

TECHNOLOGY ANALYTICS KNOWLEDGE ENTERPRISE

August 08, 2019

TAKE/BSE/2019-20
The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai – 400001
Scrip Code: 532890

TAKE/NSE/2019-20
The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai – 400051
Symbol: TAKE

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on Thursday, August 08, 2019

We wish to inform you that the Board of Directors of the Company, in its meeting held on Thursday, August 08, 2019, approved the unaudited financial results of the Company (Standalone) and together with its subsidiaries (Consolidated) for the quarter ended June 30, 2019 as recommended by the Audit Committee.

Copy of the same in the prescribed format in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, along with the Limited Review Report by the Statutory Auditors is enclosed herewith.

The meeting of Board of Directors of the Company commenced at 11:30 AM and concluded at 1:20 PM.

Please take note of the same.

Thanking you,

Yours sincerely,
For TAKE Solutions Limited

Avaneesh Singh Company Secretary

Encl: A/a:



Limited Review Report

Review Report to The Board of Directors TAKE Solutions Limited

- 1. We have reviewed the accompanying Statement cf Consolidated Unaudited Financial Results of TAKE Solutions Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the consolidation of results pertaining to the entities listed in Annexure.
- 5. Based on our review conducted and procedures performed as stated in paragraph 4 as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the

Pune Office: GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 25280081, Fax No. 25280275, Email – audit@gdaca.com

Mumbai Office: Windsor, 6th Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098



G. D. Apte & Co. Chartered Accountants

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. D. Apte & Co. Chartered Accountants

Firm Registration Number: 100515W

UDIN: 19113053AAAACI5766

Umesh S. Abhyankar

Partner

Membership Number: 113053 Chennai, August 8, 2019

Annexure

Annexure referred to in Paragraph 4 of our Limited Review Report on the Consolidated Financial Results of TAKE Solutions Limited for the Quarter and year ended March 31, 2019

Sr. No.	Particulars
Α	Subsidiaries
1	APA Engineering Private Limited
2	Ecron Acunova Limited
3	TAKE Solutions Global Holding Pte Ltd.
4	TAKE Solutions Limited ESOP Trust
5	Navitas LLP
В	Step Down Subsidiaries
1	APA Engineering Pte Ltd, Singapore
2	APA Engineering Inc., USA
3	TAKE Solutions Information Systems Pte Ltd, Singapore
4	TAKE Enterprise Services Inc., USA
5	TAKE Innovations Inc , USA
6	Navitas Life Sciences Holdings Limited, UK
7	Million Star Technologies Limited, Mauritius
8	Intelent Inc, USA
9	Navitas Life Sciences Limited, UK
10	Navitas Inc., USA
11	TAKE Supply Chain De Mexico S De RI De Cv, Mexico
12	Navitas Life Sciences S.A.S. Colombia
13	Acunova Life Science Inc., USA
14	Navitas Lifesciences Company Limited, Thailand (Formerly known as Ecron Acunova Company Limited)



Pune Office: GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 25280081, Fax No. 25280275, Email – <u>audit@gdaca.com</u> **Mumbai Office:** Windsor, 6th Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098

G. D. Apte & Co. Chartered Accountants

15	Acunova Life Sciences Limited, UK
16	Navitas Life Sciences, GmbH, Germany (Formerly known as Ecron Acunova GmbH)
17	Ecron Acunova Sdn. Bhd., Malaysia
18	Ecron Acunova Sp. Z. O. O., Poland
19	Ecron Acunova Limited , UK
20	Ecron LLC, Ukraine
21	Ecron Acunova LLC, Russia
22	Navitas Life Sciences A/S, Denmark (Formerly known as Ecron Acunova A/S)
23	Navitas Life Sciences Pte Ltd, Singapore (Formerly known as Ecron Acunova Pte Limited)





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office: 27, Tank Bund Road, Nungambakkam, Chennai 600 034 www.takesolutions.com

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2019

(₹ In Lakhs except per share data)

			Quarter Ended		
Sl. No.	Particulars	Jun 30, 2019	Mar 31, 2019	Jun 30, 2018	Year Ended Mar 31, 2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	58,274.30	53,393.80	46,754.08	203,899.85
2	Other Income	81.81	194.77	848.73	1,074.91
3	Total Revenue	58,356.11	53,588.57	47,602.81	204,974.76
4	Expenses				
	Cost of revenue	16,340.82	14,992.00	13,509.07	57,399.66
	Employee benefit expenses	16,205.18	15,571.22	13,071.01	59,162.26
	Finance cost	1,024.54	873.77	523.22	2,501.07
	Depreciation and amortisation	4,501.01	3,971.44	3,305.58	15,350.96
	Other expenses	14,772.83	14,723.74	10,851.23	48,991.88
	Total Expenses	52,844.38	50,132.17	41,260.11	183,405.83
5	Profit/(Loss) before tax (3-4)	5,511.73	3,456.40	6,342.70	21,568.93
6	Tax expense				
	Current tax	957.98	661.95	947.15	3,199.40
	Shortfall / (excess) provision of earlier years		8.08	10.96	27.31
	Deferred tax	(54.71)	80.16	(32.26)	502.99
7	Profit/(Loss) for the period (5-6)	4,608.46	2,706.21	5,416.85	17,839.23
1	Attributable to:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_,	-,	2.,500.000
	Shareholders of the company	4,510.70	2,787.92	5,341.69	17,729.64
	Non-controlling interest	97.76	(81.71)		109.59
	Non-controlling interest	57.70	(01.71)	,5.10	100,60
8	Other Comprehensive Income	1			
	a) i) Items that will not be reclassified to profit or (loss)	(38.33)	(48.72)	29.83	(42.31)
	ii) Income tax provision / (reversal) relating to the items that will not be	\	,		,
	reclassified to profit or (loss)	(12.53)	(8.77)	8.95	(13.24)
	h) i) Items that will be reclassified to profit or (loss)	2,811.17	(1,550.44)		3,213.36
	ii) Income tax provision / (reversal) relating to the items that will be		(-,,	,,	,
	reclassified to profit or (loss)	(8.10)	32.79	4.81	17.34
	Total Other Comprehensive Income	2,793.47	(1,623.18)		3,166.95
	Attributable to:	2,750117	(1,020110)	1,000170	.,
		2,793.70	(1,622.85)	4,308.73	3,167.05
	Shareholders of the company	(0.23)	(0.33)		(0.10)
	Non-controlling interest	(11.23)	(0.55)	0.20	(0.10)
9	Total Comprehensive Income	7,401.93	1,083.03	9,725.78	21,006.18
,	Attributable to:	,,,,,,,,,,	1,000100	2,720170	,
	Shareholders of the company	7,304.40	1,165.07	9,650.42	20,896.69
	• •	97.53	(82.04)		109.49
10	Non-controlling interest	1,461.91	1,461.36	1,460.28	1,461.36
	Paid-up equity share capital (Face value ₹ 1/- each)	1,401.91	1,401.30	1,400.20	1,701.30
11	Earnings per share (of ₹ 1/- each not annualised)	2.00	1.00	2.66	12.12
	(a) Basic	3.09	1.90	3.66	12.13
	(b) Diluted	3.08	1.89	3.65	12.09





Segment Wise Revenue and Results Primary Segment Information

		Quarter Ended		
Particulars	Jun 30, 2019	Mar 31, 2019	Jun 30, 2018	Mar 31, 2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1. Segment Revenue				
(i) Life Sciences	54,865.06	49,997.31	42,680.52	188,048.57
(ii) Supply Chain Management	3,409.24	3,396.49	4,073.56	15,851.28
Revenue from Operations	58,274.30	53,393.80	46,754.08	203,899.85
2. Segment Results				
(i) Life Sciences	6,883.41	5,526.53	7,767.97	28,457.72
(ii) Supply Chain Mangement	363.28	(6.41)	112.39	456.48
Total	7,246.69	5,520.12	7,880.36	28,914.20
Less: (i) Finance cost	1,024.54	873.77	523.22	2,501.07
(ii) Other Un-allocable Expenditure net off Un-allocable Income	710.42	1,189.95	1,014.44	4,844.20
Profit Before Tax	5,511.73	3,456.40	6,342.70	21,568.93

Segregation of assets, liabilities, depreciation and other non-cash expenses into various primary segments has not been carried out as the assets are used interchangeably between segments. Accordingly, no disclosure relating to segmental assets and liabilities has been made.

Note:

- 1 The Consolidated Financial Results have been reviewed and recommended by the Audit Committee at its meeting held on August 07, 2019 and approved by the Board of Directors of the company at its meeting held on August 08, 2019. The statutory auditors of the company have carried out Limited Review of the results for the quarter ended June 30, 2019.
- 2 Effective April 1, 2019, the Group adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to June 30, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right -of -use asset and corresponding lease liability. Accordingly, comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- 3 The Consolidated and Standalone financial results for the quarter ended June 30, 2019 are available on the Company's website (www.takesolutions.com) and the website of BSE (www.bseindia.com) and NSE (www.nseindia.com)
- 4 During the quarter ended June 30, 2019, employees exercised 55,007 equity shares under Employee Stock Option Scheme of the Group.
- 5 The financial results of TAKE Solutions Limited (Standalone information)

(₹ In Lakhs)

CHENNAL

		Quarter Ended		
Particulars	Jun 30, 2019	Mar 31, 2019	Jun 30, 2018	Mar 31, 2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Total income	638.75	(2,945.31)	2,676.94	5,630.74
Net profit/(loss) before tax	148.03	(3,890.05)	2,340.01	1,950.83
Net profit/(loss) for the period	158.19	(3,753.50)	2,216.04	1,739.47
Total comprehensive income	157.42	(3,757.14)	2,223.46	1,736.39

Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification,

Place : Chennai

Date: August 08, 2019

For and on behalf of the Board of Directory TIONS

Srinivasan H.R.

Luini varal

Vice Chairman & Managing Director

Limited Review Report

Review Report to
The Board of Directors
TAKE Solutions Limited

- 1. We have reviewed the accompanying statement of unaudited financial results (the statement) of TAKE Solutions Limited for the quarter ended June 30, 2019. This statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with aforesaid Indian Accounting Standard and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. D. Apte & Co. Chartered Accountants

Firm Registration Number: 100515W

UDIN: 19113053AAAACH7268

Umesh S. Abhyankar

Partner

Membership Number: 113053 Chennai, August 8, 2019





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office: 27, Tank Bund Road, Nungambakkam, Chennai 600 034 www.takesolutions.com

Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2019

(₹ In Lakhs except per share data)

	Particulars	Quarter Ended			Year Ended	
SI. No.		Jun 30, 2019	Mar 31, 2019	Jun 30, 2018	Mar 31, 2019	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
,		40.45		40.40		
2	Revenue from operations Other Income	48.46	643.46	40.19	2,195.86	
3	Total Income	590.29	(3,588.77)		3,434.88	
4	Expenses	638.75	(2,945.31)	2,676.94	5,630.74	
7	Cost of revenue	21.00	458.42	33,58	1.015.44	
		21.80	225.90		1,815.66	
1	Employee benefit expenses	186.00	223.90	121.54	682.19	
8 (Finance cost (Refer Note 3)	11.30	19.96	20.17	00.10	
	Depreciation and amortisation	45.52	240.46	161.64	80.18	
	Other expenses	226.10 490.72	944.74	336.93	1,101.88 3,679.91	
5	Total Expenses Profit/(Loss) before tax (3-4)	148.03	(3,890.05)	2,340.01	1,950.83	
6		140.03	(3,690.03)	2,340.01	1,950.83	
U	Tax expense Current tax	22.40	(151.02)	165.32	220.10	
	Deferred tax	22.68	(151.93) 15.38	(41.35)	230.19	
7		(32.84) 158.19		` '	(18.83)	
8	Profit/(Loss) for the period (5-6) Other Comprehensive Income	150.19	(3,753.50)	2,216.04	1,739.47	
0	a) i) Items that will not be reclassified to profit or (loss)	(1.08)	(5.00)	10.27	(4.27)	
		(1.00)	(3.00)	10.27	(4.27)	
	ii) Income tax provision / (reversal) relating to the items that will not be	(0.31)	(1.36)	2.85	(1.10)	
1	reclassified to profit or (loss)	(0.51)	(1.50)	2.63	(1.19)	
	b) i) Items that will be reclassified to profit or (loss)	-	- 1			
1 /	ii) Income tax provision/(reversal) relating to the items that will be	1				
	reclassified to profit or (loss)	(0.77)	(2.64)	7.42	(2.00)	
9	Total Other Comprehensive Income	(0.77) 157.42	(3.64) (3,757.14)	2,223.46	(3.08) 1,736.39	
10	Total Comprehensive Income	/				
	Paid-up equity share capital (Face value ₹ 1/- each)	1,479.34	1,479.34	1,479.34	1,479.34	
11	Earnings per share (of ₹ 1/- each) (not annualised)					
	(a) Basic (in ₹)	0.11	(2.53)	1.50	1.18	
	(b) Diluted (in ₹)	0.11	(2.52)	1.49	1.17	

Notes:

- The Standalone Financial Results have been reviewed and recommended by the Audit Committee at its meeting held on August 07, 2019 and approved by the Board of Directors of the company at its meeting held on August 08, 2019. The statutory auditors of the company have carried out Limited Review of the results for the quarter ended June 30, 2019.
- 2 Effective April 1, 2019, the Company adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to June 30, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right-of-use asset and corresponding lease liability. Accordingly, comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- The Company, on standalone basis, did not have any borrowings during the quarter ended June 2019. Adoption of Ind AS 116, 'Leases' with effect from April 01, 2019, in accordance with Indian Accounting Standards has resulted in unwinding of finance cost pertaining to lease liability which has been disclosed as such in the results.
- 4 The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- 5 During the quarter ended June 30, 2019, employees exercised 55,007 equity shares under Employee Stock Option Scheme of the Company.
- 6 Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

Aninivarant

Vice Chairman & Managing Director

For and on behalf of the Board of Directors OA

CHENNA

Place: Chennai Date: August 08, 2019